FEB 19, 2014 10:00 AM PST

Next-generation sequencing applications in advanced cancer samples: Experience with Ion AmpliSeq custom panels

Speakers
  • Medical Director of Knight Diagnostic Laboratories Director of Molecular Pathology, Oregon Health & Science University
    Biography
       
      After undergraduate studies at the Univ. of California, Berkeley, Professor Corless received his MD and PhD degrees from Washington University, St. Louis. He did his residency training in Anatomic Pathology at the Brigham & Women's Hospital, Boston, where he also completed fellowship training in GI Pathology and GU Pathology. In 1994, he joined the faculty of Oregon Health & Science University as an Assistant Professor. He has served as the residency program director in Pathology and medical director of surgical pathology for OHSU Hospital. He is an Associate Director of the Oregon Clinical & Translational Research Institute, and he presently serves as Chief Medical Officer for the OHSU Knight Diagnostic Laboratories. In addition to practicing surgical pathology, Dr. Corless has expertise in the application of molecular diagnostics to the classification and prognostication of solid tumors. He was promoted to Professor of Pathology in 2004 and is an author on over 200 publications.
       

    Abstract:
    Making precision cancer care a future reality requires novel approachesto finding treatment targets in cancers. Single-gene assays currently performed in clinical research laboratories are inadequate in the face of the rapidly growing list of genetic mutations that are potentially actionable. This presentation will focus on our experience in designing and running custom Ion AmpliSeq cancer gene panels on the Ion PGM System, an approach we are using to increase the understanding of genetic mutations in advanced cancers. Consideration will be given to detecting mutations of various types, as well as alterations in gene copy number. Critical pre-analytic factors and the integration of other technologies that define clinically significant targets
    for future treatment will also be discussed.

    Show Resources
    You May Also Like
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    JUL 30, 2019 10:00 AM PDT
    C.E. CREDITS
    JUL 30, 2019 10:00 AM PDT
    DATE: July 30, 2019TIME: 10:00am PT/ 1:00pm ET The importance of building a validation structure within your lab cannot be overstated. Once in place, the ability to identify high...
    Loading Comments...
    Show Resources